FTC puts controversial theory into practice

The FTC has put its controversial theory that many biopharma acquisitions are inherently anticompetitive into practice, blocking Sanofi’s plan to license an oral Pompe disease therapy from Maze.

The action will likely slow the development of MZE001, a glycogen synthase 1 (GYS1) inhibitor that has completed Phase I testing, delaying access to a product that could replace or augment enzyme replacement therapy. ...